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Introduction: Recurrent miscarriage (RM; 3 consecutive pregnancy losses) occurs in 1e3% of fertile
couples. No biomarkers with high predictive value of threatening miscarriage have been identiﬁed. We
aimed to proﬁle whole-genome differential gene expression in RM placental tissue, and to determine the
protein levels of identiﬁed loci in maternal sera in early pregnancy.
Methods: GeneChips (Affymetrix) were used for discovery and Taqman RT-qPCR assays for replication of
mRNA expression in placentas from RM cases (n ¼ 13) compared to uncomplicated pregnancies matched
for gestational age (n ¼ 23). Concentrations of soluble TRAIL (sTRAIL) and calprotectin in maternal serum
in normal ﬁrst trimester (n ¼ 35) and failed pregnancies (early miscarriage, n ¼ 18, late miscarriage,
n ¼ 4; tubal pregnancy, n ¼ 11) were determined using ELISA.
Results: In RM placentas 30 differentially expressed (with nominal P-value < 0.05) transcripts were
identiﬁed. Signiﬁcantly increased placental mRNA expression of TNF-related apoptosis-inducing ligand
(TRAIL; P ¼ 1.4  103; fold-change 1.68) and S100A8 (P ¼ 7.9  104; fold-change 2.56) encoding for
inﬂammatory marker calprotectin (S100A8/A9) was conﬁrmed by RT-qPCR. When compared to normal
ﬁrst trimester pregnancy (sTRAIL 16.1  1.6 pg/ml), signiﬁcantly higher maternal serum concentration of
sTRAIL was detected at the RM event (33.6  4.3 pg/ml, P ¼ 0.00027), and in pregnant women, who
developed an unpredicted miscarriage 2e50 days after prospective serum sampling (28.5  4.4 pg/ml,
P ¼ 0.039). Women with tubal pregnancy also exhibited elevated sTRAIL (30.5  3.9 pg/ml, P ¼ 0.035).
Maternal serum levels of calprotectin were neither diagnostic nor prognostic to early pregnancy failures
(P > 0.05).
Conclusions: The study indicated of sTRAIL as a potential predictive biomarker in maternal serum for
early pregnancy complications.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Recurrent miscarriage (RM), deﬁned as three or more consec-
utive pregnancy losses before 20e22 weeks pregnancy, affects 1e
3% of couples aimed at childbirth [1e3]. While fetal chromosomal
abnormalities represent the major factor behind sporadic miscar-
riages [4,5], they account for a smaller fraction of miscarriage372 7420286.
or, MI, USA.
le, TN, USA.
 license.events in RM couples [6,7]. Currently available diagnostic proce-
dures allow to identify clinical conditions increasing their risk to
pregnancy failure and to offer appropriate management options
only in 50% of RM couples [1]. The known risk factors for devel-
oping of RM are maternal thrombophilic disorders or anti-
phospholipid syndrome (5e15% in RM vs 2e5% in control women),
uterine malformations (10e25% in RM vs w5% in controls),
maternal immunological and endocrine disturbances, parental
balanced chromosomal rearrangements (3e6% of couples) [1].
Nevertheless, half of RM couples are classiﬁed as idiopathic with no
identiﬁable cause [8]. Early recognition of a potential risk to preg-
nancy loss and systematic monitoring has beneﬁcial effect in
increasing live birth rates in RM couples [8,9]. The preferred
K. Rull et al. / Placenta 34 (2013) 141e148142medical supportive care includes determination of hCG rising
serum concentrations in early pregnancy and frequent ultrasound
examinations [9]. However, only a limited number of potential
predictive biomarkers of threatening miscarriage have been
proposed [10e13].
Successful implantation, trophoblast invasion and placental
development are key processes in early pregnancy, and placental
insufﬁciency increases a risk of miscarriage and other pregnancy
complications [14,15]. Due to the difﬁculties in obtaining ﬁrst
trimester placental tissue material, only a limited number of
investigations on targeted gene expression in placentas from RM
cases have been conducted [16e18]. To our knowledge, no whole-
genome gene expression proﬁle has been reported for RM
placental tissue. The current study aimed (i) to address the whole-
genome differential gene expression in the ﬁrst trimester placental
tissue in cases of RM compared to gestational-age matched
uncomplicated pregnancies, and (ii) to determine the protein levels
of identiﬁed RM related genes in maternal serum in order to
evaluate their potential as biomarkers for predicting early preg-
nancy complications. In RM placentas, the study detected increased
expression of TNF-related apoptosis-inducing ligand (TNFSF10;
TRAIL) and S100A8 encoding for inﬂammatory marker calprotectin
(heterodimer S100A8/A9). The study indicated sTRAIL as a potential
predictive biomarker in maternal serum for early pregnancy
complications.Fig. 1. Study design. A. Patient groups analyzed in the study included patients diagnosed wit
as well as or patients with tubal pregnancy. RM was deﬁned as three and more consecutive
terminated. B. Biological material analyzed in the study included placental tissue (boxes in
Trophoblastic tissue for genome-wide expression proﬁling was obtained during the surgic
termination of normal uncomplicated pregnancy (ETP) before 12th gestational weeks. Serum
of the index pregnancy was followed until successful delivery or pregnancy loss. Treatmen
blood sampling. C. Experimental design included mRNA expression analysis and functional a
trophoblastic tissue were conﬁrmed and replicated by real-time RT-qPCR using locus-speciﬁ
by the loci exhibiting signiﬁcant overexpression in RM placentas, was measured in matern2. Methods
2.1. Study subjects
Study participants were recruited at Women’s Clinic of Tartu University
Hospital, Estonia during 2003e2011. The inclusion and analysis of collected human
samples (placenta, blood serum) in each study stage are detailed on Fig. 1. The study
was approved by the Ethics Review Committee on Human Research of the University
of Tartu, Estonia (protocols no 17/9, 16.06.2003 and 180/M-15, 23.03.2009) and was
conducted according to Declaration of Helsinki principles. A written informed
consent to participate in the study was obtained from each individual.
2.1.1. Study subjects for placental gene expression experiments
Subjects included into the analysis of differential gene expression in tropho-
blastic tissue comprised of women (i) with recurrent miscarriage with no identiﬁ-
able cause (RM patients; age 31.8  1.5 years, gestational age at the miscarriage
67.7  6.6 days) and (ii) electively terminated normal ﬁrst trimester pregnancies
with no maternal or fetal clinical complications until the termination of the preg-
nancy (ETP controls; age 26.7  1.4 years, gestational age 63.0  2.7 days) (Fig. 1A).
The recruited RM patients (n ¼ 13; parity 0e2, mean 0.7; gravidity 3e8, mean 4.3)
had experienced at least three consecutive miscarriage events. The ETP control
group (n ¼ 23; parity 0e4, mean 1.5; gravidity 2e9, mean 3.8) had no clinically
conﬁrmed miscarriages in their clinical reproductive history. The following risk
factors of pregnancy loss had been excluded in RM cases: abnormal menstrual cycle
(<21 days and >35 days), genital infections, antiphospholipid syndrome (positive
anticardiolipin and/or b2 glycoprotein 1 antibodies), thrombophilic mutations
(Factor V Leiden c.6191G>A, p.Arg506Gln; Coagulation factor II c.20210G>A) and
genital tract anomalies (ultrasound examination or hystero-sonography) in RM
women, and abnormal karyotype of either of the partners. Neither anticoagulant nor
immunological treatment was applied during the pregnancy. Three patients hadh recurrent miscarriage (RM), womenwith no miscarriages in their reproductive history
pregnancy losses. Index pregnancies at the recruitment were classiﬁed as ongoing or
gray background, solid line) and maternal serum samples (unﬁlled boxes, dashed line).
al evacuation of uterus in patients with recurrent (3rd case) miscarriage or elective
samples were taken during an ofﬁce visit at the ﬁrst trimester of pregnancy. The course
t with methotrexate or laparoscopic surgery due to tubal pregnancy was applied after
ssays. Differentially expressed genes identiﬁed from genome-wide expression proﬁle in
c Taqman assays. Concentration of proteins sTRAIL and S100A8/A9 (calprotectin) coded
al blood serum samples.
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ment period and dosage per day. Due to low number of involved patients and
multiplicity of treatment schemes, the effect on mRNA expressionwas not assessed.
At the initiation of the project, the study subjects were randomly assigned into
either the discovery (n ¼ 10) or the replication sample (n ¼ 26) set. Trophoblastic
tissue and maternal serum were sampled from recruited patients on the day of the
uterine curettage due to inevitable or delayed miscarriage (RM patients) or elective
determination of the pregnancy the patient (ETP controls). Inevitable miscarriage
was deﬁned as an ongoing process of miscarriage and delayed miscarriage as the
presence of clearly developed fetus without detectable heart beats at ultrasound
examination [19,20].
2.1.2. Study subjects for maternal serum ELISA
Enzyme-linked immunosorbent assay (ELISA) was applied for the quantiﬁcation
of sTRAIL and S100A8/A9 (calprotectin) proteins in maternal serum obtained from:
(i) same individuals studied for in the placental gene expression analysis (13 RM
cases, 23 ETP controls); (ii) patients with ongoing pregnancies recruited at the 4e
13th weeks of gestation (n ¼ 32) (Fig. 1). All maternal serum samples have been
stored at 80 C.
Among the 21 women with ongoing intrauterine pregnancy, 12 patients had no
history of miscarriage and 9 patients had experienced RM before the index preg-
nancy; additionally 11womenwere recruited at their diagnosis of a tubal pregnancy.
Among the 12 women with no history of RM, in nine cases the index pregnancy
resulted in the birth of a single live baby and in three cases the women experience
early or delayed miscarriage one to two weeks after serum sampling. Among the
nine prospectively monitored patients with the clinical history of RM, the index
pregnancy ended with a birth of single live baby in one-third of the cases (n¼ 3). The
rest of the patients (n¼ 6) experienced again loss of the index pregnancy monitored
in this study. Two cases had an early miscarriage one week after recruitment. Four
patients experienced late pregnancy loss between 16 and 27th gestational weeks
due to placental infarct, chorioamnionitis or severe Parvovirus infection. Blood
serum sampling of the 11 women with ongoing tubal pregnancy was performed
a day before treatment of the patients with methotrexate or laparoscopic surgery.
2.2. Tissue collection and RNA extraction
Placental tissue samples were obtained during elective surgical abortion of
uncomplicated pregnancy (ETP individuals) or uterine curettage due to recurrent
incomplete or delayed miscarriage (RM individuals), performed in Women’s Clinic
of Tartu University Hospital in 2003e2006. Karyotype of the collected placental
samples was unavailable. Placental samples were immediately washed with 0.9%
saline solution to remove maternal blood, snap-frozen in liquid nitrogen and stored
at 80 C or placed into RNAlater solution (Ambion, Austin TX, USA) and kept
at 20 C for RNA analysis. RNA was extracted from 200 mg of homogenized
placental tissue (containing trophoblastic and decidual material) of each subject
using TRIzol Reagent (Invitrogen, Paisley, UK) according to supplier’s recommen-
dations. To remove the residual phenol from TRIzol-based extraction, 100 ml of
extracted total RNAwas further cleaned with NucleoSpin RNA II mini spin columns
(MachereyeNagel, Düren, Germany) following the manufacturer’s protocol. Purity
level and concentration was measured using NanoDrop 1000 Spectrophotometer
(Thermo Fisher Scientiﬁc, Waltham, MA, USA). Aliquots of the RNA used for
microarray analysis were evaluated by the Agilent RNA 6000 Nano LabChip kit on an
Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA).
2.3. Microarray hybridization
Differential gene expression in placental tissues in RM (n ¼ 4) compared to
normal ﬁrst trimester uncomplicated pregnancies (n ¼ 6) was addressed using
Affymetrix Human Genome U133 plus 2.0 GeneChip according to manufacturer’s
recommendations (Affymetrix, Santa Clara, CA, USA). In brief, 1 mg of puriﬁed total
RNA was used to generate the ﬁrst strand cDNAs using SuperScript II Reverse
Transcriptase (Invitrogen) and T7-oligo (dT) primer. Next, in vitro transcription
reaction for cRNA ampliﬁcation and biotin labeling was performed in the presence of
T7 RNA Polymerase and a biotinylated nucleotide analog/ribonucleotide mix. Biotin-
labeled cRNA targets were cleaned up, fragmented, and hybridized to GeneChip
expression arrays.
2.3.1. Microarray data analysis
The microarray data generated in the study is Minimum Information About
a Microarray Experiment (MIAME) compliant and the raw data has been deposited
to a MIAME compliant database the Gene Expression Omnibus (GEO) data reposi-
tory (accession no GSE22490). Quality control (QC) was performed by affy package of
Bioconductor, an open-source software project based on R [21]. QC criteria included
comparison of average intensity, correlation with median intensity of other Gen-
eChips, GAPDH 30/50 and b-actin 30/50 , scaling factor, percentage of presence calls,
average background, intensities of positive and negative border elements (Fig. S1).
GeneChip cel-ﬁles were imported to dChip [22] (http://biosun1.harvard.edu/
complab/dchip/) and after QC analyzed using perfect match (PM)/mismatch (MM)
modeling and invariant set normalization as previously described [23,24]. Weﬁltered for the genes with high signal intensity (dChip signal threshold ¼ 100).
Sample comparison (ETP against RM) was done with t-test, and fold-changes were
calculated to evaluate differential expression of genes. Estimation of the empirical
False Discovery Rate (FDR) [25] is described in Supplemental Data, Text S1. Hierar-
chical clustering of probe sets was performed by centroid linkage and the distance
between two genes was deﬁned as 1  r. Allocation of identiﬁed genes to biological
processes was performed using Gene Ontology Annotation Database (http://www.
ebi.ac.uk/GOA/).
2.4. Reverse transcription quantitative PCR (RT-qPCR) and gene expression data
analysis
One mg of total RNA was reverse transcribed to cDNA using SuperScript III
First-Strand Synthesis SuperMix for RT-qPCR kit (Invitrogen) in accordance with
manufacturer’s instructions. Quantitative gene expression analyses were performed
with commercially available pre-made TaqMan Gene Expression Assays (Table S1;
Applied Biosystems, Carlsbad, CA, USA) using a duplex qPCR of target sequence and
endogenous control (HPRT, Applied Biosystems). The qPCR reactions (95 C for
15 min; 40 cycles of 15 s at 95 C and 1 min at 60 C) were performed in triplicate
with ABI 7900HT Real-time PCR system (Applied Biosystems) using ABsoluteQPCR
ROXMix (Thermo Fisher Scientiﬁc) or HOT FIREPol Probe qPCR Mix (Solis BioDyne,
Tartu, Estonia). Negative controls contained either non-reverse transcribed RNA or
lacked template inputs.
Relative quantiﬁcation of RT-qPCR data was determined by comparative CT
method, mean value of normalized expression was calculated by averaging three
independently calculated normalized expression values of the triplicate (Equation
No 2 in [26]). The calculations and efﬁciency corrections were carried out with
qGENE software [27]. The median expression level of the control group was selected
as a calibrator. All statistical analyses were performed by R 2.8.1, a free software
environment for statistical computing and graphics (http://www.r-project.org/).
Logistic regression model adjusted by maternal and gestational age was applied to
assess differential gene expression between RM cases and controls quantiﬁed by RT-
qPCR. The stringent Bonferroni signiﬁcance threshold for multiple testing correction
was calculated a ¼ 0.05/N ¼ 0.005, where N ¼ 10 represents the number of inde-
pendent Taqman RT-qPCR gene-probes.
2.5. ELISA analysis of sTRAIL and S100A8/S100A9 heterocomplex in maternal serum
Enzyme-linked immunosorbent assay (ELISA) was used to assess the concentra-
tion of sTRAIL (DuoSet ELISA development kit #DY375, lot #1240906; R&D Systems
Europe, Ltd., Abingdon, UK) and S100A8/A9 (MRP8/14 ELISA kit #S-1011, lot #14E-
1101; BMA Biomedicals, Augst, Switzerland) proteins in maternal serum. ELISA assays
were conducted following manufacturer’s instructions, details are provided in
Supplemental Data, Text S2. The raw data were analyzed by curve ﬁtting ReaderFit
software with 5-parameter logistic model (www.readerﬁt.com). All statistical analyses
were performed by R 2.13.1. Logistic regression models were applied to assess the
differences between the study groups in the concentration of sTRAIL and S100A8/A9 in
maternal serum. The analyses were adjusted for gestational and maternal age. Natural
log-transformation was applied to all quantitative data to improve the approximation
of normal distribution. Correlation between the relative mRNA expression (RT-qPCR)
in placenta and protein level in maternal serumwas assessedwith Pearson correlation
test (coefﬁcient r). P  0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Genome-wide differential gene expression in RM placentas
Whole-genome differential gene expression patterns in
placental tissue obtained from four recurrent miscarriage (RM) and
six uncomplicated ﬁrst trimester pregnancies were addressed
using GeneChip (Affymetrix) expression arrays (Fig. 1). In total, 27
differentially expressed genes (representing 30 transcripts with
nominal P-values < 0.05) in RM compared to control placentas
were identiﬁed, 12 genes with increased and 15 loci with reduced
transcript levels (Table 1, Fig. S3). However, none of the P-values
remained signiﬁcant after correction for multiple testing with FDR
and thus, GeneChip proﬁling was considered as exploratory anal-
ysis for hypothesis generation. For the further conﬁrmatory
experiments of the discovery observations, genes were selected
based on their fold-changes. In GeneChip dataset, alternations in
gene expression in RM placentas ranged fromw2.39 fold decrease
in ASMTL mRNA level (P-value 0.048) to more than 4.11 fold
increased expression of S100A8 transcripts (P-value 0.040). The
expression level of S100A9, the dimerization partner of S100A8 in
Table 2
RT-qPCR experimental conﬁrmation of top differentially expressed genesa in Gene-
chip proﬁling proﬁling in placentas from recurrent miscarriage.
Genea Identical discovery








(Cases n ¼ 4,
controls n ¼ 6)
(Cases n ¼ 9,
controls n ¼ 17)
(Cases n ¼ 13;
controls n ¼ 23)
Table 1
Placental gene expression patterns of recurrent miscarriage (RM; n¼ 4) and electively terminated uncomplicated pregnancies (ETP; n¼ 6) were assessed using Affymetrix HG-
U133 plus 2.0 GeneChips.
Gene (abbreviation) Fold-change 90%CI Nominal P-value
Transcripts with increased expression in RM placenta
S100 calcium binding protein A8 (S100A8) 4.11a 2.13; 10.05 0.03973
CD163 molecule (CD163) 2.94a 1.56; 7.19 0.04662
Tumor necrosis factor (ligand) superfamily, member 10 (TNFSF1 or TRAIL) 2.75a 1.93; 3.82 0.02344
Tumor necrosis factor (ligand) superfamily, member 10 (TNFSF1 or TRAIL) 2.57a 1.79; 3.69 0.02016
Secreted and transmembrane 1 (SECTM) 2.38 1.60; 3.61 0.02776
Tumor necrosis factor (ligand) superfamily, member 10 (TNFSF1 or TRAIL) 2.16a 1.49; 3.14 0.03204
Bromodomain containing 1 (BRD1) 2.12a 1.25; 5.25 0.03722
Chemokine (CeC motif) receptor 1 (CCR1) 2.03a 1.50; 2.69 0.02940
Potassium voltage-gated channel, Isk-related family, member 3 (KCNH2) 1.97 1.35; 2.94 0.03691
Bromodomain containing 1 (BRD1) 1.92a 1.34; 3.11 0.01233
S100 calcium binding protein A9 (S100A9) 1.81 1.24; 3.25 0.02793
Branched chain aminotransferase 1 (BCAT1) 1.63 1.32; 2.10 0.00362
RAB11 family interacting protein 1 (RAB11FIP1) 1.52 1.26; 1.87 0.00502
CCAAT/enhancer binding protein (C/EBP), delta (CEBPD) 1.5 1.21; 1.84 0.02857
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN) 1.39 1.23; 1.59 0.00167
Transcripts with decreased expression in RM placenta
Acetylserotonin O-methyltransferase-like (ASMTL) 2.39a 1.47; 3.51 0.04775
Calreticulin (CALR) 2.26a 1.64; 3.15 0.00636
Pleiotrophin (PTN) 2.23a 1.36; 4.72 0.02488
Neuron derived neurotrophic factor (NENF) 2.2a 1.45; 3.74 0.01409
Snail homolog 2 (Drosophila) (SNAI2) -2a 1.40; 2.76 0.02495
Thymidine kinase, soluble (TK1) 1.88 1.26; 3.01 0.03030
HOXA distal transcript antisense RNA (non-protein coding) (HOTTIP) 1.86 1.42; 2.40 0.01283
C1GALT1-speciﬁc chaperone 1 (C1GALT1C1) 1.83 1.29; 2.60 0.02606
F-box protein 22 (FBXO22) 1.83 1.33; 2.57 0.01609
Collagen, type V, alpha 1 (COL5A1) 1.67 1.31; 2.12 0.01081
Eukaryotic translation initiation factor 2B, subunit 2 beta (EIF2B2) 1.58 1.22; 2.00 0.03363
Low density lipoprotein receptor (LDLR) 1.58 1.28; 2.03 0.01001
Calumenin (CALU) 1.55 1.25; 1.96 0.01028
Synaptophysin-like 1 (SYPL1) 1.5 1.20; 1.89 0.01865
Mitochondrial ribosomal protein L19 (MRPL19) 1.4 1.21; 1.62 0.00821
The normalized log intensity values for the 30 most highly up-regulated and down-regulated differentially expressed probe sets (nominal P-value < 0.05; fold-change
difference > 1.2).
a Selected for conﬁrmation with RT-qPCR method.
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was also up-regulated (fold-change 1.81; P-value 0.040). It is
noteworthy, that three probes targeting the TRAIL (TNFSF10) gene
were among the six transcripts with the highest fold-change (fold-
changes 2.16e2.75; P-value 0.032). The ‘Volcano’ plot positioned
TRAIL (TNFSF10) among the genes exhibiting the highest differential
expression (top fold-change) in RM combined with the best
statistical support (lowest P-values) (Fig. S2). Among the detected
27 differentially expressed genes in RM placentas, an enrichment of
genes involved in cell communication and signaling (CALR, CCR1,
LYN, NENF, PTN, S100A9, TRAIL), inﬂammatory and immune








ASMTL 1.11 0.37 nd nd nd nd
BRD1 1.02 0.90 nd nd nd nd
CALR 1.14 0.41 nd nd nd nd
CCR1 1.79 0.020 1.03 0.83 1.15 0.70
CD163 2.61 0.025 1.04 0.98 1.37 0.20
NENF 1.15 0.29 nd nd nd nd
PTN 1.09 0.79 nd nd nd nd
S100A8 4.98 0.00024* 1.97 0.033 2.56 0.00079*
SNAI2 1.90 0.0020* 1.23 0.32 1.37 0.068
TRAIL 2.46 0.0027* 1.45 0.048 1.68 0.0014*
a Genes with showing a fold-change greater than two (up- and down-regulated)
in the GeneChip analysis in placental material from recurrent miscarriage (RM)
compared to controls (Table 1). Fold-change was calculated as the difference of
mean relative expression values of patient and control groups. Logistic regression
model adjusted by gestational age and maternal age was applied to assess differ-
ential gene expression between RM cases and controls quantiﬁed by RT-qPCR.
Statistically signiﬁcant (P < 0.05) tests after Bonferroni correction for multiple
testing are indicated in bold and with asterisk (*). nd: not done.3.2. Signiﬁcantly increased levels of S100A8 and TRAIL transcripts
in RM placentas
Although GeneChip proﬁling had failed to identify any tran-
scripts exhibiting statistically signiﬁcant (after FDR) evidence for
differential expression in RM placentas, it provided a list of genes
with the highest fold-changes, and thus with potential importance.
Top genes in this list were subjected to further experimental
conﬁrmation by an independent method for mRNA quantiﬁcation,
and by analyzing an independent sample set. First, ten genes
(ASMTL, BRD1, CALR, CCR1, CD163, NENF, PTN, S100A8, SNAI2, TRAIL)
showing a fold-change greater than two (up- and down-regulated)
in RM placental material were subjected to experimental conﬁr-
mation by RT-qPCR using identical samples as analyzed at the
expression microarray (Table 2). One gene, SECTM, was excluded
from RT-qPCR due to incompatibility with the pre-made Taqmanassay. mRNA quantiﬁcation by Taqman conﬁrmed signiﬁcantly
altered expression in RM placental tissue for ﬁve genes (logistic
regression: S100A8, P ¼ 2.4  104, fold-change 4.98; TRAIL,
P¼ 2.7 103, fold-change 2.46; CD163, P¼ 2.5102, fold-change
K. Rull et al. / Placenta 34 (2013) 141e148 1452.61; CCR1, P ¼ 2.0  102, fold-change 1.79; SNAI2, P ¼ 2.0  103,
fold-change e 1.90).
Next, differential expression of the ﬁve genes conﬁrmed by RT-
qPCR was further analyzed in an independent replication sample
(n ¼ 26; 9 RM placentas; n ¼ 17 controls). Signiﬁcantly increased
expression of S100A8 (P ¼ 3.3  102, fold-change 1.97) and TRAIL
(P ¼ 4.8  102, fold-change 1.45) in RM placentas (Table 2; Fig. S3)
was replicated. Combined analysis of the discovery and the repli-
cation RT-qPCR datasets enhanced the statistical support for the
increased transcript levels of S100A8 (P ¼ 7.9  104, fold-change
2.56) and TRAIL (P ¼ 1.4  103, fold-change 1.68) in placentas from
RM cases (Fig. 2; Table 2). For both genes, differential expression in
RM compared to control placentae was observed in very early
gestation at the 4e7 weeks (S100A8: fold-change 6.91, TRAIL: fold-
change 4.02) as well as in the second half of ﬁrst trimester at the 8e
13 gestational weeks (S100A8: fold-change 1.33, TRAIL: fold-change
2.00).
3.3. Signiﬁcantly elevated sTRAIL in maternal serum in early
pregnancy complications
ELISA assay was applied to estimate the concentration of the
soluble form of TNF-related apoptosis-inducing ligand (sTRAIL) in
maternal serum in normal ﬁrst trimester gestation and in cases of
failed pregnancies. The maternal serum of the failed pregnancy
cases had been collected either at the miscarriage event, or
prospectively during an ongoing gestation with no prognostic
information on its possible outcome (2e50 days prior occurrence of
unpredicted pregnancy loss). In addition, sTRAIL concentrationwas
determined in sera of patients diagnosed of tubal pregnancy, the
second most common early pregnancy complication.
In the ﬁrst trimester normal pregnancy the serum concentration
of sTRAIL exhibited its peak concentration at the 4e7th gestationalFig. 2. Signiﬁcantly increased expression of TRAIL and S100A8 in placental tissue from
recurrent miscarriage cases. TaqMan primer/probe sets were applied for quantiﬁcation
of gene expression of studied using total RNA isolated from placental tissue of recur-
rent miscarriage (RM) and electively terminated uncomplicated pregnancies (ETP) in
discovery (RM cases, n ¼ 4; ETP controls, n ¼ 6) and in replication (RM cases, n ¼ 9;
ETP controls, n ¼ 17) sample-sets. Samples of total RNA isolated from placentas of
recurrent miscarriage (RM cases; n ¼ 13) and electively terminated uncomplicated
pregnancies (ETP controls, n ¼ 23) were analyzed using TaqMan primer/probe sets.
Presented boxplots summarize the distribution of relative mRNA expression in the
joint sample set of the discovery and the replication specimen. The median expression
level of the ETP group was selected as calibrator and relative mRNA expression levels
are shown on logarithmic scale. P-values for the comparison of gene expression
between RM and ETP groups were estimated by logistic regression model with
gestational age and maternal age as cofactors.week (mean 32.4 pg/ml, median 32.6 pg/ml, range 13.7e49.5 pg/
ml; Fig. 3A) followed by a gradual decrease toward the end of the
ﬁrst trimester (mean level during the 8e13th gestational week
12.7 pg/ml, median 12.0 pg/ml, range 5.8e29.0 pg/ml). In contrast,
no similar decrease in the maternal serum sTRAIL concentration
was detected in pregnancies that ended with early miscarriage
(Fig. 3B). In cases of pregnancy loss the circulating protein level
during the 8e13th gestational week remained as high as at the
beginning of the pregnancy (mean 32.5 pg/ml, median 29.8 pg/ml,
range 17.3e50.1 pg/ml).
When compared to normal ﬁrst trimester pregnancy (sTRAIL
16.1 1.6 pg/ml, median 13.0 pg/ml), signiﬁcantly higher maternal
serum concentration of sTRAIL was detected both (i) at the recur-
rent miscarriage event (33.6  4.3 pg/ml, median 29.7 pg/ml;
P¼ 0.00027; Fig. 4), as well as (ii) in uncomplicated gestation at the
time of serum sampling, which terminatedwith an unexpected ﬁrst
trimester pregnancy loss (28.5  4.4 pg/ml, median 27.7 pg/ml;
adjusted P ¼ 0.039). In addition, women with diagnosed tubal
pregnancy also exhibited signiﬁcantly elevated concentration of
sTRAIL in their circulation (30.5  3.9 pg/ml, median 31.9 pg/ml;
adjusted P ¼ 0.035). In contrast to the cases with early pregnancy
failure, sTRAIL concentrations measured in women with an
uncomplicated pregnancy at the time of serum sampling, but
developing a late miscarriage or extremely preterm delivery of
a stillbirth baby (16e27 weeks of gestational age) did not differ
statistically from the sTRAIL serum levels in normal pregnancy
resulting in the birth of a healthy child (mean 7.6  2.3 pg/ml,
median 5.6 pg/ml; adjusted P > 0.05).
In the cases with data for both placental mRNA expression of
TRAIL and maternal serum concentration of sTRAIL, the two
measurements were signiﬁcantly correlated (Pearson’s correlation
coefﬁcient r ¼ 0.60, P ¼ 0.002).
3.4. Maternal serum level of S100A8/A9 is not indicative to early
pregnancy failure
No temporal dynamics during the ﬁrst trimester of normal and
failed pregnancies was detected in the maternal serum levels of
heterodimeric complex of S100A8/A9 (calprotectin) by ELISA assays
(Fig. 3CeD). Maternal serum levels of S100A8/A9 were neither
diagnostic (sampled at the occurred miscarriage or tubal preg-
nancy, P > 0.05) nor prognostic (sampled prospectively in patients,
who later experienced pregnancy loss, P > 0.05) to pregnancy
failures, when compared to normal pregnancy at the same gesta-
tional age. In the cases with the available data for placental mRNA
expression of S100A8 and maternal serum concentration of
S100A8/A9, the two measurements were not correlated (r ¼ 0.04,
P ¼ 0.8).
4. Discussion
The current study represents the ﬁrst genome-wide expression
proﬁling of placental tissues from recurrent miscarriage (RM)
compared to uncomplicated ﬁrst trimester pregnancy. The identi-
ﬁed 27 differentially expressed genes (nominal P < 0.05) act in the
pathways involved in cell signaling and apoptosis, inﬂammation
and environmental response (Table S2). The main limitation of the
discovery study was small sample resulting in limited statistical
power in whole-genome expression proﬁling. Additionally,
possible inclusion of some aneuploid miscarriages may have
weakened the analysis, as the karyotype of miscarried embryoswas
unavailable. The limitations of the GeneChip exploratory analysis
were overcome by two rounds of conﬁrmatory experiments using
quantitative methods (RT-qPCR and serum measurements), which
targeted individual loci. Signiﬁcantly increasedmRNA expression of
Fig. 3. Dynamics of sTRAIL (A,B) and heterocomplex S100A8/S100A9 (C,D) level in ﬁrst trimester maternal serum in normal and miscarried pregnancies. Normal pregnancy (a, c;
n ¼ 35) group included serum samples collected at the ﬁrst trimester of gestation (gestational age shown in days) from individuals whose pregnancy ended with a live birth of
a singleton baby or from women’s who had decided for elective termination of an uncomplicated pregnancy (ETP group). Early miscarriage group (b, d; n ¼ 18) included maternal
sera sampled either at the time of inevitable or delayed miscarriage (RM group) or prospectively during the ongoing index pregnancy, which spontaneously terminated with
a miscarriage before 13th gestational weeks. A logarithmic trendline describes the dynamics of sTRAIL and S100A8/S100A9 (calprotectin) concentration in serum during the
pregnancy and R2 estimate equals the square of the correlation coefﬁcient between the observed and modeled (predicted) data values. Serial serum measurements during the ﬁrst
trimester from four individuals, numbered (1) to (4) are shown with dashed line.
K. Rull et al. / Placenta 34 (2013) 141e148146apoptosis-inducing ligand TRAIL and inﬂammatory marker S100A8
was conﬁrmed (Fig. 2; Table 2). Measurement of the soluble forms
of coded proteins in maternal serum in the ﬁrst trimester gestation
revealed sTRAIL as a potential novel non-invasive predictive
biomarker for pregnancy outcome (Figs. 3 and 4). Our pilot dataset
suggests that the level of maternal serum sTRAIL is predictive of the
potential risk of pregnancy failure from the 8th gestational week. It
is noteworthy that a recent study has independently demonstrated
signiﬁcantly elevated levels of sTRAIL immediately after miscar-
riage in RM patients compared to that in ﬁrst-trimester normal
pregnant women [13].
Apoptosis plays an important role in the normal development of
human placenta and an altered balance between proliferation and
apoptosis of villous trophoblast is associated with abnormal preg-
nancies [28,29]. Increased levels of villous trophoblast apoptosis
have been identiﬁed in several placental pathologies including early
pregnancy loss, tubal pregnancy, preeclampsia, intrauterine growth
restriction and gestational trophoblastic disease [17,28e32]. TRAIL
encodes for TNF-related apoptosis-inducing ligand that is expressed
on the surface of immune cells in many tissues. It is a type II trans-
membrane protein and can be cleaved by a cysteine protease to
generate a soluble form sTRAIL [33]. In the villous placenta TRAIL is
expressed constantly throughout gestation at the protein level [34].
The expression of TRAIL in trophoblast cell culture and release of
sTRAIL into culture media was reported to decrease concordantly
during differentiation and syncytialisation processes [35]. In thepresent study a gradual decrease of maternal sTRAIL during the ﬁrst
trimester of normal pregnancy was documented. Interestingly,
TRAIL and its receptors appear to be differentially expressed in
villous placenta. Expression of TRAIL and its two decoy receptors
DcR1 and DcR2 is localized predominantly in the syncytiotropho-
blast, whereas cytotrophoblast cells have been shown to express
high levels of DR4 and DR5 [34,36] that trigger apoptotic signaling
via activation of the classic caspase-dependent ‘death’pathway [37].
In contrast, DcR1/DcR2 and a soluble TRAIL receptor osteoprotegerin
antagonize apoptotic signaling andmay protect resident cells of the
fetal membranes against the pro-apoptotic effects of TRAIL during
pregnancy [35,38]. Additionally, the trophoblast might use TRAIL as
a non-apoptotic signal inﬂuencing the cytokine milieu of the
maternal endometrium [39]. The presence of TRAIL has been also
shown at the tubal implantation site, possibly contributing to
trophoblast invasion in cases of extrauterine pregnancy [40]. Taken
together, there is an important balance between cell death and
survival signaling upon TRAIL binding [41]. The increased level of
sTRAIL may reﬂect either already initiated process of fetal rejection
or indicate to abnormal development and syncytialization of cyto-
trophoblast cells.
In addition to TRAIL, the current study detected signiﬁcantly
elevated placental mRNA expression of S100A8 in cases of RM.
Heterodimeric S100A8/A9 protein (calprotectin) has antimicrobial,
cytostatic, antiproliferative, apoptosis-inducing and chemotactic
properties and is involved in many physiological and pathological
Fig. 4. Concentration of sTRAIL in ﬁrst trimester maternal serum in normal and failed
pregnancies. Normal pregnancy (n ¼ 35) included serum samples collected at the ﬁrst
trimester of gestation from individuals whose pregnancy ended with a live birth or
from women’s who had decided for elective termination of an uncomplicated preg-
nancy (ETP group). Maternal serum in early miscarriage group had been sampled
either at the time of inevitable or delayed miscarriage (after clinical appearance,
n ¼ 13) or prospectively during the ongoing index pregnancy, which spontaneously
terminated with a miscarriage before 13th gestational weeks (n ¼ 5). Serum had been
sampled 2e50 days before clinical appearance of pregnancy loss. Late miscarriage
group (n ¼ 4) was deﬁned as a miscarriage after 12th gestational weeks (16 and 20
weeks) or as extremely preterm (24 and 27 weeks) delivery of a stillbirth baby; the
analyzed maternal serum had been sampled prospectively in the ﬁrst trimester of
pregnancy. The serum from the patients with tubal pregnancy (n ¼ 11) was taken
before application of surgical or medical treatment. The boxes represent the 25 and
75th percentiles. The median is denoted as the line that bisects the boxes. The whis-
kers are lines extending from each end of the box covering the extent of the data on 1.5
X interquartile ranges. Circles represent the outlier values. P-values reﬂecting the
differences between groups were estimated by logistic regression and adjusted for
maternal and gestational age.
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increased concentrations of S100A8/A9 in amniotic ﬂuid or in
maternal serum have been reported in intra-amniotic inﬂamma-
tion, preterm labor and preeclampsia [42e44]. However, in the
present study the increased placental mRNA expression of S100A8
and S100A9 in RM placentas was not reﬂected in the level of cal-
protectin in maternal serum and may rather reﬂect a local
inﬂammation process of the tissues at the maternalefetal inter-
phase during the rejection process of the pregnancy.
In summary, we showed TRAIL and S100A8 as differentially
expressed genes in placental tissue from recurrently miscarried
compared to uncomplicated pregnancies. Signiﬁcantly increased
level of sTRAIL was measured in maternal serum during the ﬁrst
trimester of pregnancy with unfavorable endpoint, exhibiting
potential as a predictive non-invasive biomarker for early preg-
nancy complications.Acknowledgments
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